Concetta Castilletti

List of Publications by Year
in descending order

138 papers	5,124 citations	101543 36 h-index	118850 62 g-index
144 all docs	144 docs citations	144 times ranked	9619 citing authors

#	Article	IF	Citations
1	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. Clinical Infectious Diseases, 2023, 76, e426-e438.	5.8	23
2	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 2022, 14, eabj1996.	12.4	18
3	Coordinated cellular and humoral immune responses after twoâ€dose SARSâ€CoV2 mRNA vaccination in liver transplant recipients. Liver International, 2022, 42, 180-186.	3.9	36
4	Humoral- and T-Cellâ€“Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. Neurology, 2022, 98, .	1.1	125
5	In Acute Dengue Infection, High TIM-3 Expression May Contribute to the Impairment of IFNÎ³ Production by Circulating VÎ´2 T Cells. Viruses, 2022, 14, 130.	3.3	6
6	The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates regulatory/inflammatory signals. IScience, 2022, 25, 103854.	4.1	3
7	Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up. Viruses, 2022, 14, 312.	3.3	19
8	Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. Frontiers in Immunology, 2022, 13, 846753.	4.8	37
9	Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. Clinical Infectious Diseases, 2022, 75, e552-e563.	5.8	79
10	Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. Cells, 2022, 11, 52.	4.1	11
11	Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after Immunization. Biomedicines, 2022, 10, 6.	3.2	6
12	Humoral and cellular responses to spike of Î´ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases. International Journal of Infectious Diseases, 2022, 121, 24-30.	3.3	21
13	Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. Scientific Reports, 2022, 12, 6687.	3.3	31
14	Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. Frontiers in Neurology, 2022, 13, .	2.4	18
15	COVIDâ€19 in people living with HIV: Clinical implications of dynamics of the immune response to SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 1796-1804.	5.0	38
16	A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clinical Microbiology and Infection, 2021, 27, 286.e7-286.e13.	6.0	104
17	COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, Augustâ€“October 2020. Biomolecules, 2021, 11, 425.	4.0	22
18	Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis. Cell Death and Disease, 2021, 12, 263.	6.3	89

#	Article	IF	Citations
19	Human cardiosphere-derived stromal cells exposed to SARS-CoV-2 evolve into hyper-inflammatory/pro-fibrotic phenotype and produce infective viral particles depending on the levels of ACE2 receptor expression. Cardiovascular Research, 2021, 117, 1557-1566.	3.8	21
20	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell, 2021, 184, 1821-1835.e16.	28.9	180
21	Saliva Is a Valid Alternative to Nasopharyngeal Swab in Chemiluminescence-Based Assay for Detection of SARS-CoV-2 Antigen. Journal of Clinical Medicine, 2021, 10, 1471.	2.4	19
22	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. Journal of Infection, 2021, 82, 58-66.	3.3	44
23	SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses, 2021, 13, 655.	3.3	48
24	Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. International Journal of Infectious Diseases, 2021, 107, 247-250.	3.3	38
25	Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. Microorganisms, 2021, 9, 1315.	3.6	54
26	Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. Vaccines, 2021, 9, 615.	4.4	15
27	In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. BioMed Research International, 2021, 2021, 1-21.	1.9	9
28	Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization. Antibodies, 2021, 10, 26.	2.5	1
29	Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. Molecular Therapy, 2021, 29, 2412-2423.	8.2	41
30	Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA. Cells, 2021, 10, 2541.	4.1	61
31	ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. Frontiers in Immunology, 2021, 12, 740249.	4.8	70
32	Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine. Clinical Chemistry and Laboratory Medicine, 2021, 59, 2010-2018.	2.3	41
33	Immunogenicity of Viral Vaccines in the Italian Military. Biomedicines, 2021, 9, 87.	3.2	5
34	Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19. Npj Vaccines, 2021, 6, 131.	6.0	18
35	Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021. Frontiers in Medicine, 2021, 8, 815870.	2.6	8
36	Full-length genome sequence of a dengue serotype 1 virus isolate from a traveler returning from Democratic Republic of Congo to Italy, July 2019. International Journal of Infectious Diseases, 2020, 92, 46-48.	3.3	10

#	Article	IF	Citations
37	SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy With Prolonged Viral RNA Detection. Annals of Internal Medicine, 2020, 173, 242-243.	3.9	266
38	Frequency and Duration of SARS-CoV-2 Shedding in Oral Fluid Samples Assessed by a Modified Commercial Rapid Molecular Assay. Viruses, 2020, 12, 1184.	3.3	18
39	Chikungunya Outbreak in the Republic of the Congo, 2019â€"Epidemiological, Virological and Entomological Findings of a South-North Multidisciplinary Taskforce Investigation. Viruses, 2020, 12, 1020.	3.3	15
40	Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics. Open Forum Infectious Diseases, 2020, 7, ofaa403.	0.9	17
41	Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexaâ„¢ COVID-19 direct assay. Journal of Clinical Virology, 2020, 128, 104416.	3.1	69
42	Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test. Journal of Clinical Virology, 2020, 129, 104539.	3.1	82
43	2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation. International Journal of Infectious Diseases, 2020, 93, 192-197.	3.3	145
44	Geographical Variability Affects CCHFV Detection by RTâ€"PCR: A Tool for In-Silico Evaluation of Molecular Assays. Viruses, 2019, 11, 953.	3.3	10
45	Pulmonary Involvement during the Ebola Virus Disease. Viruses, 2019, 11, 780.	3.3	6
46	VÎ´2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity. Microorganisms, 2019, 7, 350.	3.6	9
47	Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014â€"2016 Outbreak in West Africa. Viruses, 2019, 11, 373.	3.3	28
48	Orthopoxvirus Seroprevalence in Cats and Veterinary Personnel in North-Eastern Italy in 2011. Viruses, 2019, 11, 101.	3.3	4
49	Tropism of the Chikungunya Virus. Viruses, 2019, 11, 175.	3.3	85
50	Expanding Usutu virus circulation in Italy: detection in the Lazio region, central Italy, 2017 to 2018. Eurosurveillance, 2019, 24, .	7.0	29
51	Relationship Between Viremia and Specific Organ Damage in Ebola Patients: A Cohort Study. Clinical Infectious Diseases, 2018, 66, 36-44.	5.8	12
52	Lack of Zika virus antibody response in confirmed patients in non-endemic countries. Journal of Clinical Virology, 2018, 99-100, 31-34.	3.1	9
53	Whole Genome Characterization of Orthopoxvirus (OPV) Abatino, a Zoonotic Virus Representing a Putative Novel Clade of Old World Orthopoxviruses. Viruses, 2018, 10, 546.	3.3	17
54	Overproduction of IL-6 and Type-I IFN in a Lethal Case of Chikungunya Virus Infection in an Elderly Man During the 2017 Italian Outbreak. Open Forum Infectious Diseases, 2018, 5, ofy276.	0.9	12

#	Article	IF	Citations
55	Local transmission of chikungunya in Rome and the Lazio region, Italy. PLoS ONE, 2018, 13, e0208896.	2.5	33
56	The Surveillance of Chikungunya Virus in a Temperate Climate: Challenges and Possible Solutions from the Experience of Lazio Region, Italy. Viruses, 2018, 10, 501.	3.3	17
57	Molecular Characterization of Autochthonous Chikungunya Cluster in Latium Region, Italy. Emerging Infectious Diseases, 2018, 24, 178-180.	4.3	17
58	ZIKV Infection Induces an Inflammatory Response but Fails to Activate Types I, II, and III IFN Response in Human PBMC. Mediators of Inflammation, 2018, 2018, 1-6.	3.0	28
59	Prolonged detection of dengue virus RNA in the semen of a man returning from Thailand to Italy, January 2018. Eurosurveillance, 2018, 23, .	7.0	25
60	Persistence of ZIKV-RNA in the cellular fraction of semen is accompanied by a surrogate-marker of viral replication. Diagnostic implications for sexual transmission. New Microbiologica, 2018, 41, 30-33.	0.1	7
61	Human Endometrial Stromal Cells Are Highly Permissive To Productive Infection by Zika Virus. Scientific Reports, 2017, 7, 44286.	3.3	50
62	Evaluation of the inactivation effect of Triton X-100 on Ebola virus infectivity. Journal of Clinical Virology, 2017, 86, 27-30.	3.1	27
63	Imported arboviral infections in Italy, July 2014-October 2015: a National Reference Laboratory report. BMC Infectious Diseases, 2017, 17, 216.	2.9	21
64	Human Zika infection induces a reduction of IFN-Î³ producing CD4 T-cells and a parallel expansion of effector VÎ2 T-cells. Scientific Reports, 2017, 7, 6313.	3.3	35
65	Travel-Associated Zika Virus Disease. Annals of Internal Medicine, 2017, 166, 913.	3.9	0
66	Full-Length Genome Sequence of a Chikungunya Virus Isolate from the 2017 Autochthonous Outbreak, Lazio Region, Italy. Genome Announcements, 2017, 5, .	0.8	10
67	Enterovirus D68â€“Associated Acute Flaccid Myelitis in Immunocompromised Woman, Italy. Emerging Infectious Diseases, 2017, 23, 1690-1693.	4.3	26
68	Fatal Outbreak in Tonkean Macaques Caused by Possibly Novel Orthopoxvirus, Italy, January 20151. Emerging Infectious Diseases, 2017, 23, 1941-1949.	4.3	27
69	Measles Cases during Ebola Outbreak, West Africa, 2013â€“2106. Emerging Infectious Diseases, 2017, 23, 1035-1037.	4.3	21
70	Persistent detection of dengue virus RNA in vaginal secretion of a woman returning from Sri Lanka to Italy, April 2017. Eurosurveillance, 2017, 22, .	7.0	16
71	Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient. PLoS Pathogens, 2017, 13, e1006065.	4.7	14
72	Clinical, Virologic, and Epidemiologic Characteristics of Dengue Outbreak, Dar es Salaam, Tanzania, 2014. Emerging Infectious Diseases, 2016, 22, 895-899.	4.3	39

#	Article	IF	Citations
73	Zika Virus Infection in the Central Nervous System and Female Genital Tract. Emerging Infectious Diseases, 2016, 22, 2228-2230.	4.3	59
74	Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016. Eurosurveillance, 2016, 21, .	7.0	236
75	Diagnosis of Zika virus infection in pregnant women travelling to or residing in endemic areas. Lancet Infectious Diseases, The, 2016, 16, 771-772.	9.1	4
76	Sampling Surfaces for Ebola Virus Persistence After Cleaning Procedures in High-Level Isolation Settings: The Experience With 2 Patients at the Lazzaro Spallanzani National Institute for Infectious Diseases. Infection Control and Hospital Epidemiology, 2016, 37, 723-725.	1.8	4
77	Unique human immune signature of Ebola virus disease in Guinea. Nature, 2016, 533, 100-104.	27.8	170
78	Analysis of Diagnostic Findings From the European Mobile Laboratory in GuÃ©ckÃ©dou, Guinea, March 2014 Through March 2015. Journal of Infectious Diseases, 2016, 214, S250-S257.	4.0	32
79	Enabling Rapid Response to the 2014â€“2016 Ebola Epidemic: The Experience and the Results of the National Institute for Infectious Diseases Lazzaro Spallanzani. Advances in Experimental Medicine and Biology, 2016, 972, 103-122.	1.6	2
80	Three cases of Zika virus imported in Italy: need for a clinical awareness and evidence-based knowledge. BMC Infectious Diseases, 2016, 16, 669.	2.9	7
81	INMI/Emergency NGO Italian Laboratory Established In Sierra Leone during Ebola Virus Disease Outbreak in West Africa. Clinical Microbiology and Infectious Diseases, 2016, 1, .	0.1	5
82	Antiviral activity of human VÎ2 T-cells against WNV includes both cytolytic and non-cytolytic mechanisms. New Microbiologica, 2016, 39, 139-42.	0.1	5
83	Molecular Signature of the Ebola Virus Associated with the Fishermen Community Outbreak in Aberdeen, Sierra Leone, in February 2015. Genome Announcements, 2015, 3, .	0.8	3
84	IFNL4 and IFNL3 Associated Polymorphisms Strongly Influence the Spontaneous IFN-Alpha Receptor-1 Expression in HCV-Infected Patients. PLoS ONE, 2015, 10, e0117397.	2.5	10
85	Chikungunya and Its Interaction With the Host Cell. Current Tropical Medicine Reports, 2015, 2, 22-29.	3.7	7
86	Molecular Characterization of the First Ebola Virus Isolated in Italy, from a Health Care Worker Repatriated from Sierra Leone. Genome Announcements, 2015, 3, .	0.8	10
87	Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1967-73.	2.3	14
88	Temporal and spatial analysis of the 2014â€“2015 Ebola virus outbreak in West Africa. Nature, 2015, 524, 97-101.	27.8	272
89	West Nile Virus Outbreak in the Lombardy Region, Northern Italy, Summer 2013. Vector-Borne and Zoonotic Diseases, 2015, 15, 278-283.	1.5	12
90	Blood kinetics of Ebola virus in survivors and nonsurvivors. Journal of Clinical Investigation, 2015, 125, 4692-4698.	8.2	82

#	Article	IF	Citations
91	Antagonistic Antiviral Activity between IFN-Lambda and IFN-Alpha against Lethal Crimean-Congo Hemorrhagic Fever Virus In Vitro. PLoS ONE, 2015, 10, e0116816.	2.5	15
92	IgG Against Dengue Virus in Healthy Blood Donors, Zanzibar, Tanzania. Emerging Infectious Diseases, 2014, 20, 465-8.	4.3	33
93	IFN-Alpha Receptor-1 Upregulation in PBMC from HCV NaÃ¯ve Patients Carrying CC Genotype. Possible Role of IFN-Lambda. PLoS ONE, 2014, 9, e93434.	2.5	11
94	Cellular and Humoral Cross-Immunity against Two H3N2v Influenza Strains in Presumably Unexposed Healthy and HIV-Infected Subjects. PLoS ONE, 2014, 9, e105651.	2.5	5
95	Biosafety Level-4 Laboratories in Europe: Opportunities for Public Health, Diagnostics, and Research. PLoS Pathogens, 2013, 9, e1003105.	4.7	19
96	Large Human Outbreak of West Nile Virus Infection in North-Eastern Italy in 2012. Viruses, 2013, 5, 2825-2839.	3.3	36
97	Chikungunya virus infection: an overview. New Microbiologica, 2013, 36, 211-27.	0.1	188
98	A new Mycobacterium tuberculosis smooth colony reduces growth inside human macrophages and represses PDIM Operon gene expression. Does an heterogeneous population exist in intracellular mycobacteria?. Microbial Pathogenesis, 2012, 53, 135-146.	2.9	18
99	Cellular and Humoral Immune Responses to Pandemic Influenza Vaccine in Healthy and in Highly Active Antiretroviral Therapy-Treated HIV Patients. AIDS Research and Human Retroviruses, 2012, 28, 1606-1616.	1.1	12
100	Cowpox Virus in Llama, Italy. Emerging Infectious Diseases, 2011, 17, 1513-5.	4.3	27
101	Retrospective Investigation of an Influenza A/H1N1pdm Outbreak in an Italian Military Ship Cruising in the Mediterranean Sea, May-September 2009. PLoS ONE, 2011, 6, e15933.	2.5	15
102	Chikungunya virus isolates with/without A226V mutation show different sensitivity to IFN-a, but similar replication kinetics in non human primate cells. New Microbiologica, 2011, 34, 87-91.	0.1	13
103	Design and clinical application of a molecular method for detection and typing of the influenza A/H1N1pdm virus. Journal of Virological Methods, 2010, 163, 486-488.	2.1	11
104	Alkhurma Hemorrhagic Fever in Travelers Returning from Egypt, 2010. Emerging Infectious Diseases, 2010, 16, 1979-1982.	4.3	63
105	Association of Profoundly Impaired Immune Competence in H1N1vâ€Infected Patients with a Severe or Fatal Clinical Course. Journal of Infectious Diseases, 2010, 202, 681-689.	4.0	50
106	West Nile Virusâ€“Neutralizing Antibodies in Humans in Greece. Vector-Borne and Zoonotic Diseases, 2010, 10, 655-658.	1.5	35
107	Frequency of Detection of Upper Respiratory Tract Viruses in Patients Tested for Pandemic H1N1/09 Viral Infection. Journal of Clinical Microbiology, 2010, 48, 3383-3385.	3.9	30
108	Cat-to-Human Orthopoxvirus Transmission, Northeastern Italy. Emerging Infectious Diseases, 2009, 15, 499-500.	4.3	24

#	Article	IF	Citations
109	Influenza A (H1N1) in Rome, Italy in family: three case reports. Cases Journal, 2009, 2, 9123.	0.4	4
110	Crimean-Congo Hemorrhagic Fever, Southwestern Bulgaria. Emerging Infectious Diseases, 2009, 15, 983-985.	4.3	44
111	Transgenic chloroplasts are efficient sites for highâ€yield production of the vaccinia virus envelope protein A27L in plant cellsâ€. Plant Biotechnology Journal, 2009, 7, 577-591.	8.3	35
112	IFN-alpha improves Vgamma9Vdelta2 T-cells response to synthetic phosphoantigens in HCV-infected patients, suggesting combined immunotherapy strategies. Cytokine, 2009, 48, 77.	3.2	0
113	A critical reappraisal of the A226V mutation in chikungunya outbreaks: Possible role in increased pathogenesis?. Cytokine, 2009, 48, 78-79.	3.2	0
114	Recombinant interferon-Î±2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial. Vaccine, 2009, 27, 5654-5660.	3.8	39
115	GB-Virus Type C Effect on HIV Infection, Interferon System, and Dendritric Cells. Archives of Medical Research, 2008, 39, 362-363.	3.3	3
116	GB Virus Type Câ€“Driven Protection in HIV/HCV Coinfection: Possible Role of Interferon Gamma and Dendritic Cell Activation. Gastroenterology, 2008, 134, 1631-1633.	1.3	3
117	Evaluation of the effects of human leukocyte IFN-Î± on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine, 2008, 26, 1038-1049.	3.8	19
118	315 Activation of interferon response in human PBMC by Avian influenza H5N1 virus. Cytokine, 2008, 43, 317-318.	3.2	0
119	Influenza Pandemics, Immune Crossâ€Reactivity, and Pandemic Control Strategies. Journal of Infectious Diseases, 2008, 198, 294-295.	4.0	5
120	Presence of the A226V Mutation in Autochthonous and Imported Italian Chikungunya Virus Strains. Clinical Infectious Diseases, 2008, 47, 428-429.	5.8	42
121	Rapid and Biologically Safe Procedures for the Evaluation of Antigen-Specific T Cell Response to Microbial Pathogens that May be Used in the BSL-3 and BSL-4 Environment. Applied Biosafety, 2008, 13, 27-30.	0.5	3
122	Cross-subtype Immunity against Avian Influenza in Persons Recently Vaccinated for Influenza. Emerging Infectious Diseases, 2008, 14, 121-128.	4.3	81
123	Incidence of Human Herpesvirus 8 (HHV-8) infection among HIV-uninfected individuals at high risk for sexually transmitted infections. BMC Infectious Diseases, 2007, 7, 143.	2.9	23
124	Rapid Detection and Quantification of Chikungunya Virus by a One-Step Reverse Transcriptionâ€“Polymerase Chain Reaction Real-Time Assay. American Journal of Tropical Medicine and Hygiene, 2007, 77, 521-524.	1.4	44
125	Activation of VÎ³9VÎ´2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. International Immunology, 2006, 18, 11-18.	4.0	56
126	Interferonâ€Î³â€“Mediated Antiviral Immunity against Orthopoxvirus Infection Is Provided by Î³Î´ T Cells. Journal of Infectious Diseases, 2006, 193, 1606-1607.	4.0	13

#	Article	IF	Citations
127	Antiâ€“Severe Acute Respiratory Syndrome Coronavirus Immune Responses: The Role Played by Vî³9Vî´2 T Cells. Journal of Infectious Diseases, 2006, 193, 1244-1249.	4.0	78
128	Indomethacin Has a Potent Antiviral Activity against Sars Coronavirus. Antiviral Therapy, 2006, 11, 1021-1030.	1.0	163
129	Sepharose-bound, highly sulfated glycosaminoglycans can capture HIV-1 from culture medium. Carbohydrate Research, 2005, 340, 759-764.	2.3	0
130	Coordinate induction of IFN-Î± and -Î³ by SARS-CoV also in the absence of virus replication. Virology, 2005, 341, 163-169.	2.4	40
131	Human Herpesvirus 8 Infection in Patients With Cutaneous Lymphoproliferative Diseases. Archives of Dermatology, 2005, 141, 1235-42.	1.4	27
132	Hemophagocytic Syndrome in a Patient with Acute Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2004, 38, 1792-1793.	5.8	41
133	Flow Cytometry and T-Cell Response Monitoring after Smallpox Vaccination. Emerging Infectious Diseases, 2003, 9, 1468-1470.	4.3	12
134	Effects of IFNÎ± on late stages of HIV-1 replication cycle. Biochimie, 1998, 80, 745-754.	2.6	23
135	Interferon Induction by HIV-1-Infected Cells: A Possible Role of Sulfatides or Related Glycolipids. Virology, 1996, 221, 113-119.	2.4	20
136	Unidirectional budding of HIV-1 at the site of cell-to-cell contact is associated with co-polarization of intercellular adhesion molecules and HIV-1 viral matrix protein. Aids, 1995, 9, 329-335.	2.2	56
137	Interferon Induction by HIV Glycoprotein 120: Role of the V3 Loop. Virology, 1994, 205, 34-43.	2.4	44
138	Coordinate Induction of Interferon Î± and Î³ by Recombinant HIV-1 Glycoprotein 120. AIDS Research and Human Retroviruses, 1993, 9, 957-962.	1.1	43